AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Dravet Syndrome

Recent research efforts aimed at curing Dravet Syndrome.

Last updated

Dravet Syndrome

Overview

Dravet syndrome is a rare, severe developmental and epileptic encephalopathy that usually begins in the first year of life, often with prolonged seizures triggered by fever. Most cases result from a harmful change in one copy of the SCN1A gene, leaving brain inhibitory neurons with too little NaV1.1 sodium-channel activity; this makes the brain more prone to seizures. People with Dravet syndrome commonly develop drug-resistant seizures alongside developmental delay or intellectual disability, problems with movement, behavior, sleep, and autonomic function, and an increased risk of sudden unexpected death in epilepsy (SUDEP). International consensus Zorevunersen trial

Current care is intensive but not curative: it combines seizure-rescue plans, avoidance of triggers where possible, developmental and supportive therapies, and multiple antiseizure treatments. International consensus supports valproate and clobazam as core therapies, with stiripentol, fenfluramine, pharmaceutical cannabidiol, ketogenic diet, and vagus-nerve stimulation used according to an individual’s needs; sodium-channel-blocking antiseizure drugs can worsen seizures in typical SCN1A loss-of-function Dravet syndrome. International consensus

Scope of Recent Research (2020–present)

Research since 2020 has shifted substantially from suppressing seizures alone toward correcting the biological consequence of SCN1A haploinsufficiency—having only one adequately functioning gene copy. The two leading clinical strategies are RNA treatment that increases output from the healthy SCN1A copy and one-time AAV9 gene-regulation therapy aimed at restoring SCN1A activity in inhibitory neurons; meanwhile, gene replacement, CRISPR-based activation or editing, and cell-based approaches remain largely preclinical. These programs are promising disease-modifying candidates, but no therapy has yet been proven to cure Dravet syndrome. Zorevunersen trial ETX101 preclinical study SCN1A reactivation study

Major Breakthroughs and Emerging Therapies

RNA therapy: zorevunersen. Zorevunersen, formerly STK-001, is an antisense oligonucleotide—a short synthetic strand of nucleic acid—given into cerebrospinal fluid by lumbar puncture. It is designed to prevent inclusion of a nonproductive SCN1A RNA segment, thereby increasing production of NaV1.1 from the person’s remaining healthy SCN1A copy rather than changing DNA itself. In the Phase 1–2a MONARCH and ADMIRAL studies and their open-label extensions, 81 participants received zorevunersen; longer-term extension data showed reductions in convulsive-seizure frequency and reported improvements in caregiver- and clinician-assessed functioning, quality of life, and adaptive behavior. Zorevunersen trial

AAV9 gene regulation: ETX101. ETX101 is a one-time intracerebroventricular AAV9 treatment that delivers an engineered transcription factor intended to raise SCN1A expression selectively in GABAergic inhibitory neurons. This approach avoids trying to package the unusually large SCN1A coding sequence into a standard AAV vector and instead turns up the patient’s own gene in the cell type most central to the disorder. In a 2022 mouse and nonhuman-primate study, the predecessor platform increased SCN1A/NaV1.1 expression in inhibitory neurons, reduced spontaneous and heat-induced seizures, improved survival in Dravet-model mice, and had preliminary tolerability findings in primates. ETX101 preclinical study

Early clinical findings for ETX101 are encouraging but remain preliminary and sponsor reported. In September 2026, Encoded Therapeutics reported sustained seizure-frequency reductions through 52 weeks, progressive adaptive-behavior gains, and no treatment-related serious adverse events in its small, open-label Phase 1/2 POLARIS program; these observations require confirmation in the randomized pivotal study. Updated POLARIS data

Gene replacement, gene reactivation, and gene editing. Directly replacing SCN1A is technically difficult because its coding sequence is larger than the usual AAV packaging capacity. Nonetheless, researchers have shown that a high-capacity adenoviral vector carrying full-length SCN1A could lessen seizures, protect against sudden death, and improve some motor and behavioral outcomes when delivered to adolescent Dravet-model mice after symptoms had begun. Separate conditional mouse experiments found that reactivating Scn1a after symptom onset could rescue major disease features, supporting the principle that meaningful benefit may still be possible after infancy. SCN1A transfer study SCN1A reactivation study

CRISPR-based approaches are also being developed, chiefly as ways to activate the healthy SCN1A gene rather than cut DNA. In a 2020 mouse study, a nuclease-inactive Cas9 transcriptional activator plus guide RNAs increased Scn1a expression in inhibitory neurons and improved febrile-seizure and behavioral measures. Foundation-funded work is now extending this logic toward base editing, which could potentially correct certain single-letter disease-causing variants, but these methods remain far from human testing and would need to establish precise brain delivery and long-term safety. CRISPR activation study 2024 DSF grant awards

Clinical Trials and Experimental Approaches

Zorevunersen is the most clinically advanced disease-modifying candidate. Its completed Phase 1–2a studies and open-label extensions provided the first peer-reviewed clinical evidence that increasing NaV1.1 expression may improve both seizures and broader outcomes, although the uncontrolled design cannot separate drug effect fully from expectation, selection, or natural-history effects. The global Phase 3 EMPEROR trial is randomized, double-blind, and sham controlled, and evaluates efficacy, safety, and tolerability in children and adolescents with Dravet syndrome; it is sponsored by Stoke Therapeutics. Zorevunersen trial EMPEROR trial record

Encoded Therapeutics’ POLARIS program includes open-label Phase 1/2 studies—ENDEAVOR, WAYFINDER, and EXPEDITION—of ETX101 in infants, children, and adolescents with SCN1A-positive Dravet syndrome. ENDEAVOR Part 2 is a randomized, double-blind, sham-controlled pivotal study in children aged 6 months to under 4 years, designed to assess seizure and neurodevelopmental outcomes; the first participant was dosed in May 2026. Encoded clinical studies ETX101 pivotal-study announcement

Methodologies and Scientific Approaches

Researchers combine several disease models to determine whether a treatment corrects both seizures and developmental features. These include genetically engineered mice with Scn1a loss, patient-derived induced pluripotent stem cells (iPSCs) differentiated into neurons, and three-dimensional forebrain organoids. Human cell models are particularly valuable for testing whether an intervention restores inhibitory-neuron firing and reduces abnormal synchronized network activity in cells carrying a patient’s own variant. Dravet iPSC-organoid model Human neuronal-network model

For delivery, programs use intrathecal antisense oligonucleotides or direct cerebrospinal-fluid delivery of viral vectors, while preclinical groups measure NaV1.1 protein, electroencephalography, seizure diaries, neurodevelopmental scales, adaptive behavior, and survival. The ETX101 program is also studying blood markers, functional neuroimaging, and quantitative electrophysiology as possible biomarkers that could show whether SCN1A restoration is affecting the brain before long-term clinical outcomes are known. Encoded clinical studies Augmenting NaV1.1 assay platform

Leading Institutions and Funding

The field is driven by collaborations among pediatric epilepsy centers, academic laboratories, patient organizations, and biotechnology companies. Stoke Therapeutics and Biogen are advancing zorevunersen; Encoded Therapeutics is advancing ETX101 with clinical investigators including major pediatric neurology centers in the United States, United Kingdom, and Australia. Encoded raised $275 million in Series F financing in September 2026 to support ETX101 pivotal development, expansion studies, and manufacturing scale-up. ETX101 financing announcement

The Dravet Syndrome Foundation (DSF) is an especially important catalyst for high-risk early research. DSF’s current grant mechanisms include Transformational Science Grants of $500,000 over three years and Research or Clinical Research Grants of $250,000 over two years. In 2024, DSF awarded $1.4 million across five projects, including work at the Allen Institute on circuit-selective whole-SCN1A delivery and a Children’s Hospital of Philadelphia/MIT-Harvard collaboration evaluating base editing. DSF grant programs 2024 DSF grant awards

Strengths, Limitations, and Challenges

The principal strength of current curative-intent research is that it addresses a well-defined disease mechanism: insufficient NaV1.1 activity from SCN1A loss of function. Zorevunersen has now produced peer-reviewed longer-term clinical data, and ETX101 has moved from compelling cell-selective animal evidence into clinical testing, making Dravet syndrome one of the more advanced precision-genetics programs in epilepsy. Zorevunersen trial ETX101 preclinical study

Important uncertainties remain. Zorevunersen requires repeated lumbar delivery and its clinical evidence before Phase 3 is largely open label; ETX101 is irreversible after dosing, has been studied in small numbers of participants, and has not yet produced randomized efficacy data. For all genetic strategies, researchers must determine the safest amount, timing, and brain-cell specificity of SCN1A restoration, whether benefits persist for decades, whether older patients can regain lost developmental function, and whether therapies will work across the diverse SCN1A variants and comorbidities represented in Dravet syndrome. Zorevunersen trial Updated POLARIS data SCN1A reactivation study

Outlook and Future Directions

As of October 13, 2026, Dravet syndrome does not have a cure, but the field has progressed from theoretical genetic correction to late-stage RNA therapy and pivotal testing of one-time gene regulation. The most important near-term milestones are randomized Phase 3 results for zorevunersen, randomized pivotal outcomes for ETX101, and evidence that seizure reduction is accompanied by durable gains in cognition, communication, daily functioning, and SUDEP risk. A true cure would need not only sustained seizure freedom or major seizure reduction, but also safe lifelong restoration of development and function across the full Dravet population. EMPEROR trial record ETX101 pivotal-study announcement

References

Don't see your disease? Request a report